Eagle Faces Down Nasdaq Delisting After Failing To File Critical Financial Documents
Hearing Before Nasdaq’s Hearing Panel Scheduled For 11 July As Delays Accumulate
Executive Summary
Eagle Pharmaceuticals has responded to the Nasdaq’s threat to delist its securities from the stock exchange after racking up a number of overdue financial documents. Generics Bulletin delves into the ongoing saga.